A new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of ...
GlobalData on MSN
Moderna’s mRNA flu vaccine passes FDA AdCom, review underway
The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age ...
The Food and Drug Administration has declined to review Moderna’s application for the first mRNA-based flu vaccine, a decision that shocked the company and that comes as the agency plans to tighten ...
An FDA panel voted 9-0 that the benefits of Moderna’s mRNA-1010 flu vaccine outweigh risks for adults aged 50 and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results